Search

Accelerate Your Glucan Synthase Inhibitors (Triterpenoids) based Antifungal Drug Discovery & Development: CRO Service for Early-Stage Research

At Creative Biolabs, we understand the critical challenges and immense potential within this field. We are a leading Contract Research Organization (CRO) dedicated to accelerating early-stage antifungal drug discovery and development. With our specialized expertise in triterpenoid-based glucan synthase inhibitors, we offer comprehensive services designed to help you navigate the complexities of this demanding research area and bring life-saving therapies to patients faster. Request a quote

The Promise of Triterpenoids in Antifungal Drug Discovery

Fig.1 Glucan Synthase Inhibitors antifungal drugs testing. (Creative Biolabs Authorized)

The fungal cell wall is a unique and important component for the survival of fungi and does not exist in mammalian cells, making it an ideal target for antifungal drugs. Specifically, β-(1,3)-D-glucan is a major structural polysaccharide of the fungal cell wall, and its synthesis is catalyzed by the enzyme β-(1,3)-D-glucan synthase. Inhibiting this enzyme disrupts cell wall integrity, leading to osmotic stress and ultimately, fungal cell lysis and death. Triterpenoids, a vast and diverse class of natural products, have garnered significant attention for their wide range of biological activities, including promising antifungal properties.

Our Comprehensive CRO Services for Early-Stage GPI Anchor Pathway Inhibitor Discovery

Target Services
Hit Identification Services
Preclinical In Vitro and In Vivo Services

Target Identification & Validation

  • Bioinformatic analysis to identify novel fungal glucan synthase targets.
  • Gene knockout and knockdown studies in fungal models to validate target essentiality.
  • Enzymatic assays for high-throughput screening of glucan synthase activity.

High-throughput Screening (HTS) & Hit Identifications

  • Large-scale screening of diverse chemical libraries, including natural product extracts and synthetic triterpenoid libraries.
  • Identification of initial hit compounds with promising glucan synthase inhibitory activity.
  • Structure-Activity Relationship (SAR) Studies: Comprehensively analyze and understand the relationship between chemical structure and biological activity to guide further compound optimization.

Preclinical in vitro and in vivo Efficacy Studies

  • Antifungal susceptibility testing (MIC, MFC) against a broad panel of clinically relevant fungal pathogens, including multidrug-resistant strains (Candida spp., Aspergillus spp., Cryptococcus neoformans, C. auris, etc.).
  • Time-kill kinetics to assess fungicidal versus fungistatic activity.
  • Mechanism of action studies: confirming glucan synthase inhibition through various assays (e.g., cell wall disruption assays, β-(1,3)-D-glucan content analysis.).
  • Cytotoxicity assays against mammalian cells to assess selectivity and potential host toxicity.
  • Antifungal combination studies to explore synergistic effects with existing therapies.
  • Biofilm inhibition and eradication assays.
  • In vitro ADME assays (e.g., microsomal stability, plasma protein binding, Caco-2 permeability).
  • Preclinical in vivo efficacy models to evaluate the efficacy of lead compounds.
  • In vivo PK studies in animal models to determine bioavailability, half-life, and tissue distribution.

Fig.2 Research on Glucan Synthase Inhibitors Antifungal drugs. (Creative Biolabs Authorized)

Discover How We Can Help - Request a Consultation

Mechanism of Action: How Glucan Synthase Inhibitors Work

  • Compromised Cell Wall Integrity: The fungal cell wall becomes weak and porous, losing its structural rigidity.
  • Osmotic Instability: The weakened cell wall can no longer withstand the osmotic pressure differences between the fungal cell and its environment.
  • Cell Lysis and Death: This osmotic imbalance leads to rapid cell lysis, effectively killing the fungal pathogen.

Advantages of Triterpenoid-based Antifungals

Novel Chemical Space

Triterpenoids offer a structurally distinct scaffold, potentially overcoming existing resistance mechanisms developed against other antifungal classes.

Diverse Biological Activities

Beyond antifungal activity, many triterpenoids exhibit anti-inflammatory, anticancer, and immunomodulatory effects, potentially offering multi-targeted therapeutic benefits.

Oral Bioavailability Potential

Unlike some existing glucan synthase inhibitors, triterpenoids have shown potential for oral formulations, offering greater patient convenience and broader accessibility.

Favorable Safety Profile

Many naturally occurring triterpenoids have a long history of traditional use and may offer a more favorable safety profile compared to some synthetic compounds.

Despite these advantages, challenges remain in triterpenoid-based drug development, including issues with water solubility, bioavailability, and the need for targeted structural modifications to enhance pharmacological effects. This is where Creative Biolabs' expertise becomes invaluable.

Target Customer Groups

  • Pharmaceutical and Biotechnology Companies: Seeking to augment their internal drug discovery capabilities or outsource specialized projects in antifungal research.
  • Academic and Research Institutions: Requiring expert support for translating promising early-stage discoveries into viable drug candidates.
  • Small and Medium-Sized Enterprises (NDAs): Looking for comprehensive R&D support without the overhead of establishing in-house infrastructure.
  • Venture Capital-Backed Startups: Aiming to de-risk and accelerate their innovative antifungal programs.

The fight against invasive fungal infections is a global priority. By leveraging the power of glucan synthase inhibition and the unique potential of triterpenoids, we can unlock new frontiers in antifungal therapy. Contact us today to discuss your specific research needs and discover how Creative Biolabs can accelerate your triterpenoid-based antifungal drug discovery and development program. Let us be your trusted partner in bringing desperately needed therapies to patients worldwide.

FAQs

What fungal pathogens can you work with?

We have expertise in working with a wide range of human fungal pathogens, including various Candida species (e.g., C. albicans, C. glabrata, C. auris), Aspergillus species (e.g., A. fumigatus), and Cryptococcus neoformans.

Do you offer customized assay development?

Yes, we specialize in developing and validating custom assays to address unique research questions and specific compound characteristics.

How do you ensure data quality, integrity, and confidentiality?

We implement stringent quality control measures, employ robust data management systems, and adhere to strict confidentiality protocols, including comprehensive Non-Disclosure Agreements (NDAs), to protect your intellectual property.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutic


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2025 Creative Biolabs. All Rights Reserved.

Inquiry Basket